Document Detail

Isotypes and opsonophagocytosis of pneumococcus type 6B antibodies elicited in infants and adults by an experimental pneumococcus type 6B-tetanus toxoid vaccine.
MedLine Citation:
PMID:  9596761     Owner:  NLM     Status:  MEDLINE    
Streptococcus pneumoniae is a major respiratory pathogen of infants, children, and the elderly. Polysaccharide vaccines have been useful in adult populations but do not elicit protective immunity in infants and young children. To enhance their immunogenicity, vaccines of pneumococcal polysaccharides conjugated to proteins are being developed. In this study antibody levels and opsonic activities were compared in sera of infants and adults injected with pneumococcal polysaccharide type 6B (Pn6B) conjugated to tetanus toxoid (TT) (Pn6B-TT). Healthy infants were injected with Pn6B-TT; group A was injected at 3, 4, and 6 months of age, and group B was injected at 7 and 9 months of age. A booster injection was given at 18 months. Adults were injected once. Antibodies were measured by enzyme-linked immunosorbent assay and radioimmunoassay, and their functional activities were measured by opsonophagocytosis of radiolabelled pneumococci. In adults, increases in immunoglobulin M (IgM), IgG, IgA, IgG1, and IgG2 to Pn6B were observed. Infants reached adult levels of IgG1 anti-Pn6B after the primary injections. After the booster injection the infant groups had total IgG- and IgM-Pn6B antibody levels similar to those of adults. After the booster injection, IgG1 was the dominant infant anti-Pn6B isotype and at a level higher than in vaccinated adults, but IgA and IgG2 antibodies remained at very low levels. Opsonic activity increased significantly after Pn6B-TT injections; the highest infant sera showed opsonic activity comparable to that of vaccinated adults. Overall, opsonic activity correlated best with total and IgG anti-Pn6B antibodies (r = 0.741, r = 0.653, respectively; n = 35) and was highest in sera with high levels of all Pn6B antibody isotypes. The results indicate the protective potential of a pneumococcal 6B polysaccharide protein conjugate vaccine for young infants.
G Vidarsson; S T Sigurdardottir; T Gudnason; S Kjartansson; K G Kristinsson; G Ingolfsdottir; S Jonsson; H Valdimarsson; G Schiffman; R Schneerson; I Jonsdottir
Publication Detail:
Type:  Clinical Trial; Comparative Study; Journal Article; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  Infection and immunity     Volume:  66     ISSN:  0019-9567     ISO Abbreviation:  Infect. Immun.     Publication Date:  1998 Jun 
Date Detail:
Created Date:  1998-06-25     Completed Date:  1998-06-25     Revised Date:  2013-04-18    
Medline Journal Info:
Nlm Unique ID:  0246127     Medline TA:  Infect Immun     Country:  UNITED STATES    
Other Details:
Languages:  eng     Pagination:  2866-70     Citation Subset:  IM    
Departments of Immunology, Reykjavik, Iceland.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Age Factors
Antibodies, Bacterial / blood*
Bacterial Vaccines / immunology*
Child, Preschool
Evaluation Studies as Topic
Immunoconjugates / immunology
Immunoglobulin G / blood
Opsonin Proteins / blood
Polysaccharides, Bacterial / immunology*
Streptococcus pneumoniae / immunology*
Tetanus Toxoid / immunology
Reg. No./Substance:
0/Antibodies, Bacterial; 0/Bacterial Vaccines; 0/Immunoconjugates; 0/Immunoglobulin G; 0/Opsonin Proteins; 0/Polysaccharides, Bacterial; 0/Tetanus Toxoid

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Liposomes containing lipid A serve as an adjuvant for induction of antibody and cytotoxic T-cell res...
Next Document:  Characterization of a sar homolog of Staphylococcus epidermidis.